ClinicalTrials.gg
Status unknownNCT03326765Updated Oct 17, 2018

Characterizing Sleep Disorders in Children and Adults With Tuberous Sclerosis Complex (TSC)

An interventional study of Questionnaires and electroencephalogram (EEG) in Sleep Disorder, sponsored by Universitair Ziekenhuis Brussel. Status unknown at 1 site in Belgium. Open to participants aged 1 Day to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-17.

Sponsored by Universitair Ziekenhuis Brussel · Not applicable, Interventional, and Other

The sponsor has not verified this record recently (last verified Oct 2018), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
1 Day to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 17 studies in Sleep Wake Disorders with a site in Belgium — 5 open to participants now, 8 under way, 4 of them phase 3. Sleep Wake Disorders · Belgium.

Planned enrollment
9th of 12
60 · median 110
Started
2017
the only one that year
No phase
6 of 17
1 open now
Registered
3rd of 17
by date
Lead sponsor
1 of 17
Universitair Ziekenhuis Brussel

Among the 17 studies in Sleep Wake Disorders with a site in Belgium, this one is the 9th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2017, is one of 6 with no phase, and was the 3rd registered.

Sleep Wake Disorders

747 studies on the registry are indexed under Sleep Wake Disorders; 182 are open to participants now.

This study's planned enrollment of 60 is close to the median of 66 across 531 interventional studies indexed under Sleep Wake Disorders.

Browse Sleep Wake Disorders studies →

Open to participants now

5 of the 17 studies in Sleep Wake Disorders with a site in Belgium are open now, in 12 countries. Each count lists the studies.

All 5 open studies →

Who these studies take

Of the 109 Sleep Wake Disorders studies recruiting now, 36 (33%) set no upper age limit and 53 (49%) stop at 75 or younger; 22 take children under 18; 24 take healthy volunteers.

This study: 1 Day to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →
Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Sleep Wake Disorders with a site in Belgium, or all of them as a file.
02

Study summary

The proposed research project is aimed at further characterization of sleep problems and evaluation of their impact in children and adults with TSC, excluding epilepsy as contributing factor. Questionnaire-based studies have shown that sleep problems occur in up to half of the children and a third of adults with tuberous sclerosis complex (TSC). However, there is only limited information on the nature of sleep problems and their impact on patients with TSC and their families.

Read the detailed description

Questionnaire-based studies have shown that sleep problems occur in up to half of the children and a third of adults with tuberous sclerosis complex (TSC). However, there is only limited information on the nature of sleep problems and their impact on patients with TSC and their families. It is known from a questionnaire-based study in children with TSC that they often wake early or wake frequently during the night, and that they can be more tired during the day. In some children, sleep-problems seem to be related to the presence of seizures during the night. This has been confirmed in a study on 10 children with TSC and epilepsy by a combination of polysomnography (sleep study) and electroencephalography (EEG). A questionnaire-based study in adults also revealed the association with epilepsy features, and showed influence of mental health complaints on sleep.

Sleep structure and quality will be assessed through formal sleep studies (polysomnography and actigraphy). The influence of abnormal brain activity on sleep will be mapped by simultaneous recording of brain activity by means of EEG. The impact of sleep disorders will be determined through interviews with individuals with TSC and their relatives. The investigators will also use questionnaires and diaries to supplement their findings.

Importance: It is expected that the results of this study will 1) improve our understanding of sleep problems in TSC, 2) provide additional information on the influence of TSC on sleep, 3) give a more in-depth view on the impact of sleep problems on the lives of individuals with TSC and their families, 4) increase awareness about sleep problems in TSC, and 5) contribute to a better management of sleep problems by patients and families.

03

Conditions studied

  • Sleep Disorder

Keywords

  • tuberous sclerosis complex (TSC)
  • Children
  • Adults
04

Who can participate

Ages eligible
1 Day to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Children and adults with definite TSC based on the 2012 Consensus Conference Diagnostic

Exclusion criteria

Exclusion Criteria:

  • daily alcohol intake
  • pregnancy
  • caffeine abuse (>4 cups/day)
  • shift work
  • drug abuse
  • anti-depressive therapy
  • medications as benzodiazepine, melatonin, phenobarbital and antihistamines
  • the presence of clinical or electrographic seizures.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Other
    Children

    Questionnaires electroencephalogram (EEG) Actigraphy polysomnography

    Other: Questionnaires · Procedure: electroencephalogram (EEG) · Procedure: polysomnography · Procedure: Actigraphy

  • Other
    Adults

    Questionnaires electroencephalogram (EEG) Actigraphy polysomnography

    Other: Questionnaires · Procedure: electroencephalogram (EEG) · Procedure: polysomnography · Procedure: Actigraphy

Interventions

  • OtherQuestionnaires

    * Epworth sleepiness scale * Pittsburgh sleep quality Index (PSQI) * EQ-5D Adults * Pediatric Daytime Sleepiness scale (PDSS) * Sleep disturbance Scale for Children (SDSC * EQ-5D Children * Sleaping diary

  • Procedureelectroencephalogram (EEG)

    is an electrophysiological monitoring method to record electrical activity of the brain

  • Procedurepolysomnography

    type of sleep study, is a multi-parametric test used in the study of sleep and as a diagnostic tool in sleep medicine

  • ProcedureActigraphy

    type of sleep study based on bracelet around the wrist

06

What researchers measure

Primary outcomes

  1. characterize the sleep phenotype of TSC in children and adults without epilepsy

    - Sleep efficiency (SE%): the percentage ratio between total sleep time and time in bed (TST/TIB\*100)

    Time frame: 1 night

07

Study locations

1 of 1 sites recruiting
  • Universitair Ziekenhuis Brussel
    Jette, Vlaams Brabant 1090, Belgium
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2017 (actual). Primary completion is estimated for Nov 2019, 25 months after the start.

Of 208 non-industry interventional studies with no phase under Sleep Wake Disorders, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 40. This study's planned 25 months is above that.

Counting every sponsor, half of 243 studies reached it within 19 months; a quarter within 6 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2017
First posted
Oct 31, 2017
StartActual
Sep 27, 2017
Primary completionEst.
Nov 1, 2019
CompletionEst.
Nov 30, 2019
Last update
Oct 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03326765
Responsible party
Veerle Van Mossevelde (Study coordinator, Universitair Ziekenhuis Brussel) — Principal investigator
First posted
Oct 31, 2017
Start date
Sep 27, 2017
Primary completion
Nov 1, 2019 (estimated)
Completion
Nov 30, 2019 (estimated)
Last update
Oct 17, 2018

Study contacts

Veerle Van Mossevelde, Study coordinator
Contact
veerle.vanmossevelde@uzbrussel.be
+3224763134
Dirk De Clippeleir, Study coordinator
Contact
dirk.declippeleir@uzbrussel.be
+3224763580
Anna Jansen, PhD, MD
principal investigator · Universitair Ziekenhuis Brussel
Sonia De Weerdt, MD
principal investigator · Universitair Ziekenhuis Brussel
Alessandra Pereira,, PhD, MD
principal investigator · Department of Pediatrics School of Medicine, PUCRS, Brazil
Magda Nunes, PhD, MD
principal investigator · Director, School of Medicine, PUCRS, Brazil; Brain Instititute of Rio Grande do Sul, Brazil
Oliviero Bruni, PhD, MD
principal investigator · Department of Developmental and Social Psychology, Sapienza University of Rome, Italy
Paolo Curatolo, PhD, MD
principal investigator · Director, Child Neurology and Psychiatry Unit, Systems Medicine Department, Tor Vergata University of Rome, Italy

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion